Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Biotherapy (Dordrecht, Netherlands)|January 1, 1993
The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from gastric or colorectal cancersK Satoh, N Kan, T Okino, et al.
Surgery Today|January 1, 1994
The induction of specific antitumor immunity by in vivo treatment with interleukin-1 and sonicated tumor extract in a murine modelT Harada, N Kan, T Okino, et al.
Human Cell|September 1, 1988
[Clinical therapeutic effect of adoptive immunotherapy using IL-2-cultured autologous lymphocytes]N Kan, T Okino, M Nakanishi, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1993
Sequential immunotherapy using interleukin-1 followed by interleukin-2 of ascitic MOPC104E-bearing miceT Harada, N Kan, T Okino, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1990
[Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy]N Kan, T Okino, K Satoh, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapyK Satoh, N Kan, T Okino, et al.
Japanese Journal of Cancer Research : Gann|November 7, 1999
Two target regions of allelic loss on chromosome 9 in urinary-bladder cancerK Ohgaki, K Minobe, K Kurose, et al.
Cancer Research|October 1, 1990
Effect of heat treatment on tumor cells and antitumor effector cellsK Mise, N Kan, T Okino, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1989
Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytomaN Kan, T Okino, M Nakanishi, et al.
Nihon Gan Chiryo Gakkai Shi|August 20, 1989
[Oral administration of OK-432 (picibanil). (8th report) clinical application: its immunomodulatory effects on the patients with gastrointestinal cancers]Y Nio, K Ohgaki, T Tsuchitani, et al.
Pageof 6